The emergence of the “omicron” variant of the novel coronavirus caused a major stir on Wall Street last week. But was it an overreaction? More
Articles
Deciphera Pharmaceuticals Is Trying to Beat Financial Cancer — And Losing Hard
Deciphera is a biotech full of hope but lagging on financial performance. The recent selloff in DCPH stock is justified by its poor trials. More
Gores Guggenheim Could Be the Next Big EV Play, But Don’t Buy Shares Yet
Its planned merger with Polestar can make GGPI stock a strong EV bet, but patient investors who wait to buy will see much bigger rewards. More
Naked Brand’s Pivot to Commercial EV Technology Is Sudden, But Promising
It's been a tough year for NAKD stock holders. However, a change in Naked Brand's business model could propel the share price above $1. With acquiring shares from Cenntro Automotive Group, Naked Brand could be a competitor in the electric vehicle industry. More
Beware of Fake News
Short sellers issued a warning that Standard Lithium couldn't meet its own claimed results, but the warning turned out to not hold water. More
Decentraland Offers Ample Opportunity as the Metaverse Takes Off
Decentraland's VR platform offers a brave new world for creators, entrepreneurs, and early adopters as FB becomes Meta Platforms. More
NUZE Stock Alert: What’s Going on With Short Squeeze Play NuZee Today?
NuZee has been rising all day as short squeeze momentum propels it forward. Here's why you should be watching NUZE stock. More
